每经头条（nbdtoutiao）——新能源重卡爆单了，11月销量同比增长178%！两班倒都供不应求，客户直 接进厂催单，这情景十年难遇 （记者 曾健辉） 每经AI快讯，新诺威（SZ 300765，收盘价：35.62元）12月22日晚间发布公告称，石药创新制药股份有 限公司董事会于本日（2025年12月22日）收到公司董事CAI LEI（蔡磊）先生的书面辞职报告。CAI LEI先生申请辞任公司董事职务，辞任后不再担任公司任何职务。 2024年1至12月份，新诺威的营业收入构成为：功能食品及原料行业占比92.91%，生物制药行业占比 4.43%，其他业务占比2.66%。 截至发稿，新诺威市值为500亿元。 ...

广发医疗保健股票A（004851）基金经理为吴兴武。 截至发稿，吴兴武累计任职时间10年317天，现任基金资产总规模106.41亿元，任职期间最佳基金回报 89.3%， 任职期间最差基金回报-42.12%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 12月22日，新诺威涨5.1%，截至发稿，报36.46元/股，成交3.12亿元，换手率0.63%，总市值512.11亿 元。新诺威股价已经连续3天上涨，区间累计涨幅20.87%。 资料显示，石药创新制药股份有限公司位于河北省石家庄市栾城区张举路62号,香港湾仔港湾道18号中 环广场32楼3206室，成立日期2006年4月5日，上市日期2019年3月22日，公司主营业务涉及功能食品的 研发、生产与销售。主营业务收入构成为：功能食品及原料88.93%，生物制药8.91%，其他2.16%。 从基金十大重仓股角度 数据显示，广发基金旗下1只基金重仓新诺威。广发医疗保健股票A（004851）三季度增持6400股 ...

据天眼查APP显示，石药创新制药股份有限公司成立于2006年04月05日，注册资本140459.2944万人民 币。（数据宝） 数据宝统计，截至14:42，新诺威成交额10.05亿元，创2025年4月30日以来新高。最新股价上涨 11.60%，换手率2.09%。上一交易日该股全天成交额为5.87亿元。 （文章来源：证券时报网） ...

从基金十大重仓股角度 数据显示，诺安基金旗下1只基金重仓新诺威。诺安精选价值混合A（001900）三季度增持47.06万股， 持有股数95.43万股，占基金净值比例为4.9%，位居第八大重仓股。根据测算，今日浮盈赚取约160.32 万元。 12月19日，新诺威涨5.4%，截至发稿，报32.81元/股，成交1.19亿元，换手率0.26%，总市值460.85亿 元。 资料显示，石药创新制药股份有限公司位于河北省石家庄市栾城区张举路62号,香港湾仔港湾道18号中 环广场32楼3206室，成立日期2006年4月5日，上市日期2019年3月22日，公司主营业务涉及功能食品的 研发、生产与销售。主营业务收入构成为：功能食品及原料88.93%，生物制药8.91%，其他2.16%。 诺安精选价值混合A（001900）成立日期2019年2月28日，最新规模2.82亿。今年以来收益63.35%，同 类排名426/8098；近一年收益57.49%，同类排名527/8067；成立以来收益59.87%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、 ...

12月18日，新诺威涨5.2%，截至发稿，报30.54元/股，成交2.07亿元，换手率0.50%，总市值428.96亿 元。 嘉实互融精选股票A（006603）基金经理为郝淼。 截至发稿，郝淼累计任职时间6年338天，现任基金资产总规模53.42亿元，任职期间最佳基金回报 183.83%， 任职期间最差基金回报-37.63%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，石药创新制药股份有限公司位于河北省石家庄市栾城区张举路62号,香港湾仔港湾道18号中 环广场32楼3206室，成立日期2006年4月5日，上市日期2019年3月22日，公司主营业务涉及功能食品的 研发、生产与销售。主营业务收入构成为：功能食品及原料88.93%，生物制药8.91%，其他2.16%。 从基金十大重仓股角度 数据显示，嘉实基金旗下1只基金重仓新诺威。嘉实互融精选股票A（006603）三季度增持150.61万股， 持有股数320.11万股，占基金净值比例为4.5 ...

据港交所文件：石药创新制药股份有限公司向港交所提交上市申请书。 ...

Group 1 - The core point of the article highlights the recent performance of XinNuoWei, which saw a 5.2% increase in stock price, reaching 33.39 CNY per share, with a total market capitalization of 46.899 billion CNY [1] - XinNuoWei's main business involves the research, production, and sales of functional foods, with revenue composition being 88.93% from functional foods and raw materials, 8.91% from biopharmaceuticals, and 2.16% from other sources [1] Group 2 - From the perspective of major fund holdings, data shows that Nuoan Fund has a significant position in XinNuoWei, with its Nuoan Selected Value Mixed A Fund increasing its holdings by 470,600 shares in the third quarter, now holding a total of 954,300 shares, which constitutes 4.9% of the fund's net value [2] - The Nuoan Selected Value Mixed A Fund has achieved a year-to-date return of 73.05%, ranking 163 out of 8,134 in its category, and a one-year return of 57.82%, ranking 429 out of 8,056 [2] - The fund manager, Tang Chen, has been in charge for 2 years and 343 days, with the fund's total asset size at 1.317 billion CNY, achieving a best return of 76.25% during his tenure [2]

Group 1 - The core viewpoint of the news is that XinNuoWei's stock price increased by 5.18%, reaching 33.27 CNY per share, with a trading volume of 260 million CNY and a turnover rate of 0.64%, resulting in a total market capitalization of 46.731 billion CNY [1] - XinNuoWei, established on April 5, 2006, and listed on March 22, 2019, is primarily engaged in the research, production, and sales of functional foods, with revenue composition being 88.93% from functional foods and raw materials, 8.91% from biopharmaceuticals, and 2.16% from other sources [1] Group 2 - From the perspective of major circulating shareholders, E Fund's Chuangye ETF (159915) reduced its holdings by 1.3253 million shares in the third quarter, now holding 7.868 million shares, which accounts for 0.63% of circulating shares, with an estimated floating profit of approximately 12.9035 million CNY [2] - E Fund's Chuangye ETF (159915) was established on September 20, 2011, with a current scale of 110.2 billion CNY, achieving a year-to-date return of 47.69% and a one-year return of 32.24%, ranking 574 out of 4216 and 858 out of 3951 in its category, respectively [2] Group 3 - The fund managers of E Fund's Chuangye ETF are Cheng Xi and Liu Shurong, with Cheng having a tenure of 9 years and 193 days and a total fund asset size of 250.121 billion CNY, achieving a best return of 131.04% and a worst return of -67.89% during his tenure [3] - Liu Shurong has a tenure of 8 years and 121 days, managing assets totaling 141.127 billion CNY, with a best return of 194.12% and a worst return of -48.01% during his tenure [3]

Core Points - The core issue revolves around insider trading allegations against Pan Weidong, an executive director of the company, resulting in a fine of 5 million RMB imposed by the China Securities Regulatory Commission (CSRC) [1][2] Group 1: Insider Trading Allegations - Pan Weidong was found to have engaged in insider trading by purchasing over 2.74 million shares of Shiyao Innovation, amounting to approximately 99.99 million RMB, between December 8 and December 20, 2023, while being aware of undisclosed information regarding a restructuring transaction [1][2] - The CSRC determined that Pan Weidong violated the Securities Law of the People's Republic of China, leading to the administrative penalty [2] Group 2: Company Actions and Announcements - Shiyao Innovation announced plans to acquire another wholly-owned subsidiary of Shiyao Group and to raise matching funds, with the restructuring transaction being led by Pan Weidong at the time [1] - The restructuring transaction was ultimately terminated and not completed, as disclosed in a subsequent announcement by Shiyao Innovation [2]

Core Viewpoint - The executive director of CSPC Pharmaceutical Group, Pan Weidong, has been fined 5 million yuan for insider trading related to a subsidiary's restructuring transaction [1][3]. Group 1: Insider Trading Incident - The incident traces back to December 8, 2023, when CSPC's indirect subsidiary, CSPC Innovation, announced that its largest shareholder, Enbipu, planned to increase its stake in CSPC Innovation by up to 100 million yuan within six months [2]. - Pan Weidong, who was the chairman of CSPC Innovation at the time, was aware of insider information regarding a restructuring transaction before it was made public [2]. - Between December 8 and December 20, 2023, Pan utilized Enbipu's securities account to purchase 2.7426 million shares of CSPC Innovation, totaling approximately 99.9888 million yuan [2]. Group 2: Regulatory Actions - The China Securities Regulatory Commission (CSRC) determined that Pan's actions constituted insider trading and mandated him to handle the illegal securities holdings, imposing a fine of 5 million yuan [3]. - CSPC Pharmaceutical Group stated that the penalty is not expected to negatively impact the overall business operations of the company [4]. Group 3: Company Background and Financial Performance - CSPC Innovation, established in 2006 and previously known as CSPC New Drug Co., Ltd., went public on the Shenzhen Stock Exchange in 2019 [4]. - For the first three quarters of 2025, CSPC Innovation reported a revenue of 1.593 billion yuan, reflecting a year-on-year increase of 7.71%, while the net profit attributable to shareholders was a loss of 24.0489 million yuan, a decline of 117.26% year-on-year [5].